Laura B. Goddard

Array ( [id] => 18597267 [patent_doc_number] => 20230272062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent [patent_app_type] => utility [patent_app_number] => 18/059719 [patent_app_country] => US [patent_app_date] => 2022-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11798 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18470298 [patent_doc_number] => 20230204583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => KERATINS AS BIOMARKERS FOR CERVICAL CANCER AND SURVIVAL [patent_app_type] => utility [patent_app_number] => 18/057949 [patent_app_country] => US [patent_app_date] => 2022-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11979 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436065 [patent_doc_number] => 20230183359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 18/058194 [patent_app_country] => US [patent_app_date] => 2022-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18391422 [patent_doc_number] => 20230159640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => CARRIER-PD-L1 BINDING AGENT COMPOSITIONS FOR TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 18/057165 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17857 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20076298 [patent_doc_number] => 12350333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Checkpoint regulator antagonists [patent_app_type] => utility [patent_app_number] => 18/053878 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 74 [patent_no_of_words] => 27379 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537528 [patent_doc_number] => 20230242626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 [patent_app_type] => utility [patent_app_number] => 18/052840 [patent_app_country] => US [patent_app_date] => 2022-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537528 [patent_doc_number] => 20230242626 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => COMPOSITION FOR TREATMENT AND PREVENTION OF COVID-19 [patent_app_type] => utility [patent_app_number] => 18/052840 [patent_app_country] => US [patent_app_date] => 2022-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18470307 [patent_doc_number] => 20230204592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERS [patent_app_type] => utility [patent_app_number] => 18/051551 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18470307 [patent_doc_number] => 20230204592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERS [patent_app_type] => utility [patent_app_number] => 18/051551 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861901 [patent_doc_number] => 20230416336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/975887 [patent_app_country] => US [patent_app_date] => 2022-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861901 [patent_doc_number] => 20230416336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/975887 [patent_app_country] => US [patent_app_date] => 2022-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17975887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582939 [patent_doc_number] => 20230265197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/049793 [patent_app_country] => US [patent_app_date] => 2022-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596084 [patent_doc_number] => 20230270875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES [patent_app_type] => utility [patent_app_number] => 18/048986 [patent_app_country] => US [patent_app_date] => 2022-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 94315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449598 [patent_doc_number] => 20230190874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ANTIGEN BINDING PROTEINS, COMPOSITIONS, AND METHODS OF USING THEREOF [patent_app_type] => utility [patent_app_number] => 17/938492 [patent_app_country] => US [patent_app_date] => 2022-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938492 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20201721 [patent_doc_number] => 12404490 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => AGGF1 immunogenic compositions [patent_app_type] => utility [patent_app_number] => 17/938270 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2533 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18164387 [patent_doc_number] => 20230030982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => METHOD FOR TREATING CANCER BY ADMINISTRATION OF ANTIBODIES THAT BIND TO EXTRACELLULAR REGION PORTION OF MCEMP1 PROTEIN [patent_app_type] => utility [patent_app_number] => 17/960354 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18164387 [patent_doc_number] => 20230030982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => METHOD FOR TREATING CANCER BY ADMINISTRATION OF ANTIBODIES THAT BIND TO EXTRACELLULAR REGION PORTION OF MCEMP1 PROTEIN [patent_app_type] => utility [patent_app_number] => 17/960354 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20187103 [patent_doc_number] => 12398208 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-26 [patent_title] => PSMA binding antibody and uses thereof [patent_app_type] => utility [patent_app_number] => 17/934232 [patent_app_country] => US [patent_app_date] => 2022-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 44 [patent_no_of_words] => 21353 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18250846 [patent_doc_number] => 20230077885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/946094 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18250846 [patent_doc_number] => 20230077885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/946094 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946094 [rel_patent_id] =>[rel_patent_doc_number] =>)